Zafgen Inc (NASDAQ:ZFGN) has been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.00.
A number of analysts recently weighed in on ZFGN shares. Zacks Investment Research cut shares of Zafgen from a “buy” rating to a “hold” rating in a report on Friday, September 1st. ValuEngine raised shares of Zafgen from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th.
Shares of Zafgen (ZFGN) traded down 2.54% on Thursday, hitting $3.45. 36,486 shares of the stock were exchanged. The firm’s 50 day moving average price is $3.52 and its 200 day moving average price is $3.79. Zafgen has a one year low of $2.89 and a one year high of $5.46. The firm’s market cap is $94.82 million.
Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.03. During the same quarter last year, the firm posted ($0.55) earnings per share. Equities analysts anticipate that Zafgen will post ($2.23) earnings per share for the current year.
In related news, Director Frances K. Heller bought 10,000 shares of the stock in a transaction on Friday, October 13th. The shares were purchased at an average price of $3.90 per share, with a total value of $39,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 21.20% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC boosted its position in shares of Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 10,327 shares in the last quarter. Algert Global LLC bought a new position in shares of Zafgen during the 2nd quarter valued at about $123,000. Wells Fargo & Company MN boosted its position in shares of Zafgen by 1,290.3% during the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 40,400 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Zafgen during the 2nd quarter valued at about $259,000. Finally, LMR Partners LLP bought a new position in shares of Zafgen during the 2nd quarter valued at about $299,000. Institutional investors own 48.53% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/26/zafgen-inc-zfgn-receives-average-rating-of-hold-from-brokerages.html.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.